Immuno-Oncology And Immunotherapy – Part B Volume 190, in the Methods in Cell Biology series, continues the legacy of this premier serial with quality chapters authored by leaders in the field. In this update, chapters include Machine learning methods to assess metastatic burden, Development of pre-clinical models, Tumor microenvironment analysis by multiparametric flow cytometry or/and mass cytometry, Measure of therapy induced cell senescence, and much more.
Les mer
1. Flow cytometry analysis of myeloid derived suppressor cells using 6 color labeling Rocío Flores-Campos, Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Carlos Jiménez-Cortegana, Luis de la Cruz-Merino and Víctor Sánchez-Margalet 2. In vitro screening methods of novel immune checkpoint inhibitors related to T cell infiltration and anti-PD-1 resistance Zhuoying He, Xiuman Zhou, Youmei Xiao and Yanfeng Gao 3. Machine learning approach to assess brain metastatic burden in preclinical models. Jessica Rappaport, Quanyi Chen, Tomi McGuire, Amélie Daugherty-Lopès and Romina Goldszmid 4. Cytofluorometric analysis of the maturation and activation of bone marrow-derived dendritic cells to assess immunogenic cell death Faye Naessens, Iuliia Efimova, Mariia Saviuk and Dmitri V. Krysko 5. Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Chiara Cappello, Olga Maria Pittino, Patrizia Nanni, Arianna Palladini and Pier-Luigi Lollini 6. Spatial immunophenotyping of FFPE tissues by imaging mass cytometry Carolina Mangana and Barbara B. Maier 7. Processing human colon cancer specimens for in vitro cytotoxicity assays Sofia Mensurado, Rafael Blanco-Domínguez, Mariana Carreira, Leandro Barros and Bruno Silva-Santos 8. An orthotopic metastatic xenograft model of colorectal cancer Rafael Blanco-Domínguez, Sofia Mensurado, Leandro Barros, Mariana Carreira and Bruno Silva-Santos 9. A preclinical mouse model of hepatic metastasis to instruct effective treatment modalities Arianna Pocaterra, Antonio Citro, Chiara Gnasso, Tamara Canu, Anna Tosi, Antonio Rosato, Antonio Esposito, Lorenzo Piemonti and Anna Mondino 10. Myeloid-derived suppressor cells: Identification and function Paola Vacca, Maria Teresa Bilotta, Lorenzo Moretta and Nicola Tumino 11. Measuring the impact of therapy-induced senescence on NK cell phenotypes in cancer Shreya R. Chowdhury, Katherine C. Murphy, Chaitanya N. Parikh, Kelly D. DeMarco, Lin Zhou and Marcus Ruscetti 12. Selective expansion of anti-tumor innate lymphocytes in long-term cultures after a single BCG pulse María-José Felgueres, Gloria Esteso, Nacho Aguiló and Mar Valés-Gómez
Les mer
Edited by one of the best scientists in the field, this series presents the latest updates in the field of cell biology
Authored by established and active cell biologists and immunologist and drawn from international sources. Includes in-depth coverage and detailed protocols. Present a highly specialized group of topics that delve deep into new updates and future prospects.
Les mer

Produktdetaljer

ISBN
9780443296161
Publisert
2024-11-13
Utgiver
Vendor
Academic Press Inc
Vekt
520 gr
Høyde
229 mm
Bredde
152 mm
Aldersnivå
P, UP, 06, 05
Språk
Product language
Engelsk
Format
Product format
Innbundet
Antall sider
236

Volume editor

Biographical note

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Norma received her master’s degree in health biology from Paris Saclay. In 2013, she joined the laboratory of Dr. Guido Kroemer at the Centre de Recherche des Cordeliers (Paris, France) and at Gustave Roussy (Villejuif, France), the largest center for oncological patients in Europe. She worked on several projects linked to immunosurveillance, culminating with her obtaining her PhD in 2017 with an original work on “Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance”. She then moved to Weill Cornell Medicine to join the program in radiation and immunity under the mentorship of Dr. Galluzzi. Her current research is focused on investigating resistance to immunotherapy in a mouse model of HR+ breast cancer. Maud Charpentier received her M.Sc. in Cellular Biology and her Ph.D. in Immunology from the University of Nantes, France. She chose to pursue an academic career and continued her postdoctoral training in the United States. She joined the Department of Radiation Oncology at Weill Cornell Medicine under the mentorship of Dr. Sandra Demaria. Maud has a long-standing interest in the anti-tumor immune response and its role in controlling cancer progression and treatment outcomes. Her research focuses on understanding the synergy between radiation therapy and immunotherapy in solid tumors, with the aim of overcoming resistance to treatment and developing innovative therapeutic approaches in preclinical models.